Navigation Links
SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
Date:12/8/2011

MOUNTAIN VIEW, Calif., Dec. 8, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the SEQUEL study were published in The American Journal of Clinical Nutrition, a peer-reviewed journal with broad, multidisciplinary readership. The SEQUEL study evaluated the long-term efficacy and safety of Qnexa in 676 overweight and obese subjects with cardiometabolic disease. In addition to 10% sustained weight loss, the study also found that significantly more placebo patients became diabetic over the two years as compared to patients treated with Qnexa. The data suggest that Qnexa, in conjunction with lifestyle modification, may provide a well-tolerated and effective option for the sustained treatment of obesity and the potential to prevent many in this population from progressing to type 2 diabetes.

"Recent data show that diabetes, like obesity, has become a rapidly growing epidemic, with nearly 1 in 10 adults potentially affected by the disease," said lead investigator W. Timothy Garvey M.D., director of the Nutrition Obesity Research Center, University of Alabama at Birmingham. "Results from the SEQUEL study underscore Qnexa's potential as a non-surgical option for sustained weight loss and improvements in comorbidities in overweight and obese patients."

Specific results as published in AJCN are as follows:

  • Patients treated with Qnexa had significant, sustained weight loss compared to those in the placebo group over two years. 
  • Average weight loss at week 108 was -9.3% and -10.5%, respectively, for the mid- and top-dose as compared to -1.8% for the placebo group (least-squares mean ITT-LOCF).
  • Qnexa patients had improved cardiovascular and metabolic risk factors and a decrease in the need for associated medications in comparison with the placebo group.
  • Placebo patients had a three times greater li
    '/>"/>

    • SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
    2. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
    3. SequelMed EMR Version 8 Certified by Ohio Board of Pharmacy
    4. Sequel Systems, Inc. Meaningful Use EHR Receives ONC-ATCB 2011/2012 Certification
    5. Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology
    6. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
    7. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
    8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
    9. TIs new MSP430™ microcontrollers enable more performance and higher precision in home automation, industrial and portable medical applications
    10. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
    11. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2013)... VANCOUVER, British Columbia , May 22, 2013  OncoGenex ... the development of novel therapeutics to target mechanisms of treatment ... investigational compounds, custirsen and OGX-427, will be presented as "Trials ... of the American Society of Clinical Oncology (ASCO) in ... 4. Despite the availability of drugs that ...
    (Date:5/21/2013)... , May 21, 2013 Reaching a ... process, the National Association of Boards of Pharmacy ® ... the .PHARMACY domain suffix has passed the Internet Corporation ... intends to launch the .PHARMACY gTLD by the end ... to legitimate online pharmacies and related entities that are ...
    (Date:5/21/2013)... SAN FRANCISCO , May 21, 2013 /PRNewswire/ ... meeting of the American Psychiatric Association show that ... statistically and clinically meaningful response and remission in ... acute phase of therapy, which were maintained through ... acute treatment, 62 percent of patients achieved symptomatic ...
    Breaking Medicine Technology:OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 2OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 3OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 4OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 5NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 4
    ... TOKYO and CHIPPENHAM, England, October 7 ,Sosei ... and Vectura,Group plc ("Vectura"; LSE: VEC), announce ... efficacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data ...
    ... of Gastroenterology Annual ... ... two Phase 3,studies presented at the American College of Gastroenterology Annual,Scientific ... rates than lansoprazole among patients with more,severe grades of erosive esophagitis ...
    Cached Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 2Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 3
    (Date:5/22/2013)... Rochester, NY (PRWEB) May 22, 2013 ... can now have access to Adapt Courseware’s new ... curriculum in an adaptive framework that responds based ... Adapt Courseware , the provider of comprehensive adaptive ... experience, is continuing to develop introductory level general ...
    (Date:5/22/2013)... Jersey (PRWEB) May 22, 2013 Ethos ... gift card system, fit for the busy lifestyle of the ... select a design appropriate for the occasion, whether it is ... an apology note, or any other occasion. , Clients should ... Jersey spa gift card designs on the Ethos Spa’s ...
    (Date:5/22/2013)... TheBeautyPlace.com features Toppik and Bosley hair fibers, two ... of thinning or balding hair. Hair loss treatments can be ... hair loss during this waiting period, one can use these ... alternative to hair transplant surgery in general. , Bosley ... extremely effective way to eliminate the appearance of balding and ...
    (Date:5/22/2013)... NJ (PRWEB) May 22, 2013 The health ... In some states, up to twenty-seven percent of all ... all bankruptcies of private citizens in the U.S. are related ... also affects prescription drugs, meaning that many patients cannot afford ... even get them filled at all. That's why MedicationDiscountCard.com ...
    (Date:5/22/2013)... NJ (PRWEB) May 22, 2013 Officials ... today that its cicada services are now in full ... year that the cicada cycle emerges. , “The ... the year that they will emerge, so we’re now ... they are well protected during the invasion,” said R. ...
    Breaking Medicine News(10 mins):Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 3Health News:Ethos Spa Skin And Laser Center Has Launched Their Customizable Gift Certificates 2Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:Lyrica Discount Cards Now Available From MedicationDiscountCard.com 2Health News:Alliance Commercial Pest Control, Inc. Now Offering Cicada Protection Services 2
    ... researcher has co-authored an international study that revealed a drug ... a rare lung disease in women. The life-threatening disease ... The clinical trial of the drug -- called sirolimus -- ... therapy for the lung disease, lymphangioleiomyomatosis, or LAM. LAM ...
    ... The wrist size of overweight or obese children and teens ... says a new study. Italian researchers measured the wrist ... They also used a painless nuclear imaging technique on about ... areas of the wrist more precisely. Blood tests were ...
    ... MONDAY, April 11 (HealthDay News) -- A drug commonly prescribed ... treating the mild stage of the disease, a new study ... effective in treating moderate to severe Alzheimer,s disease, "in mild ... works," said lead researcher Dr. Lon S. Schneider, a professor ...
    ... new discovery published online in The FASEB Journal ( ... likely to benefit from breast cancer drug therapies. If ... it would represent a significant advance for breast cancer ... some people. In addition, some drugs have side effects ...
    ... How your carotid artery moves can reveal your risk of ... study this vessel aspect in more detail thanks to a ... with suspected coronary artery disease, reveals a thesis from the ... arteries is associated with a risk of future heart disease, ...
    ... the journal Investigational New Drugs and conducted by researchers ... molecule inhibitors are showing promise in blocking STAT3, a ... osteosarcoma. These small molecule inhibitors one derived from ... as a new, non-toxic treatment for these deadly tumors. ...
    Cached Medicine News:Health News:OHSU expert co-authors study finding treatment for rare lung disease 2Health News:Drug Memantine Ineffective for Mild Alzheimer's, Study Finds 2Health News:Drug Memantine Ineffective for Mild Alzheimer's, Study Finds 3Health News:Tiny antibody fragments raised in camels find drug targets in human breast cancer cells 2Health News:New potential atherosclerosis risk marker discovered 2Health News:New study finds compounds show promise in blocking STAT3 signaling as treatment for osteosarcoma 2
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: